Trials in Cardiology.pptx
0 likes27 views
This document summarizes two upcoming cardiovascular trials to be presented at the ESC 2023 Congress. The STOP DAPT-3 trial will compare P2Y12 inhibitor monotherapy with dual antiplatelet therapy after PCI and found monotherapy is not superior due to higher rates of ischemic events. The FIRE trial found complete revascularization guided by full physiology to lower complications compared to culprit-only PCI in myocardial infarction patients. Both trials provide new insights into antiplatelet regimens and revascularization strategies after cardiovascular procedures.
Trials in Cardiology.pptx
- 1. Ground Breaking Trials in Cardiology Presenter: Dr. AFM Azim Anwar azimbinanwar@gmail.com Chairperson: Dr. Md. Faisal Ibn Kabir, FCPS, MD Assoc. Professor, Dept Of Cardiology, BSMMU. mfi_kabir@yahoo.com 27 August,2023
- 6. RIVER TRIAL, ESC 2023 CONGRESS
- 22. Stop DAPT-3 trial will be published on ESC 2023 P2Y12 I monotherapy Prasugrel vs DAPT , after PCI In first month Bleeding more common in DAPT Ischemic events common in monotherapy Overall, Monotherapy is not superior
- 27. 2023 ESC Congress, 25 August
- 32. FIRE TRIAL on ESC 2023 Complete Physiology guided Revascularization to lower risk of complication, vs culprit only PCI in MI
- 45. Disclaimer: All of the above information are property of their rightful owners. I just collaborated them in a single presentation. Dr. AFM Azim Anwar https://www.researchgate.net/profile/Afm-Anwar https://orcid.org/my-orcid?orcid=0000-0002-2489-5000